616 related articles for article (PubMed ID: 12588351)
21. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
de Romeuf C; Hilbert L; Mazurier C
Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
[TBL] [Abstract][Full Text] [Related]
22. Platelet aggregation by membrane-expressed A1 domains of von Willebrand Factor is dependent on residues Asp 560 and Gly 561.
Schulte am Esch J; Robson SC; Cruz MA
Biochem Biophys Res Commun; 2003 Mar; 302(4):873-7. PubMed ID: 12646253
[TBL] [Abstract][Full Text] [Related]
23. Molecular genetics of type 2 von Willebrand disease.
Fressinaud E; Mazurier C; Meyer D
Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
[TBL] [Abstract][Full Text] [Related]
24. Identification of a new type 2M von Willebrand disease mutation also at position 1324 of von Willebrand factor.
Hilbert L; Fressinaud E; Ribba AS; Meyer D; Mazurier C;
Thromb Haemost; 2002 Apr; 87(4):635-40. PubMed ID: 12008946
[TBL] [Abstract][Full Text] [Related]
25. Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib.
Rabinowitz I; Randi AM; Shindler KS; Tuley EA; Rustagi PK; Sadler JE
J Biol Chem; 1993 Sep; 268(27):20497-501. PubMed ID: 8376405
[TBL] [Abstract][Full Text] [Related]
26. Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease.
Ribba AS; Christophe O; Derlon A; Cherel G; Siguret V; Lavergne JM; Girma JP; Meyer D; Pietu G
Blood; 1994 Feb; 83(3):833-41. PubMed ID: 8298143
[TBL] [Abstract][Full Text] [Related]
27. Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (vWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent function of vWF.
Hilbert L; Gaucher C; Mazurier C
Blood; 1995 Aug; 86(3):1010-8. PubMed ID: 7620154
[TBL] [Abstract][Full Text] [Related]
28. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion.
Miura S; Li CQ; Cao Z; Wang H; Wardell MR; Sadler JE
J Biol Chem; 2000 Mar; 275(11):7539-46. PubMed ID: 10713059
[TBL] [Abstract][Full Text] [Related]
29. Molecular genetics of von Willebrand disease.
Mazurier C; Ribba AS; Gaucher C; Meyer D
Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
[TBL] [Abstract][Full Text] [Related]
30. Binding site on human von Willebrand factor of bitiscetin, a snake venom-derived platelet aggregation inducer.
Matsui T; Hamako J; Matsushita T; Nakayama T; Fujimura Y; Titani K
Biochemistry; 2002 Jun; 41(25):7939-46. PubMed ID: 12069583
[TBL] [Abstract][Full Text] [Related]
31. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib.
Girma JP; Takahashi Y; Yoshioka A; Diaz J; Meyer D
Thromb Haemost; 1990 Oct; 64(2):326-32. PubMed ID: 1702906
[TBL] [Abstract][Full Text] [Related]
32. Shielding the front-strand beta 3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibalpha.
Bonnefoy A; Yamamoto H; Thys C; Kito M; Vermylen J; Hoylaerts MF
Blood; 2003 Feb; 101(4):1375-83. PubMed ID: 12393553
[TBL] [Abstract][Full Text] [Related]
33. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha.
Martin C; Morales LD; Cruz MA
J Thromb Haemost; 2007 Jul; 5(7):1363-70. PubMed ID: 17389010
[TBL] [Abstract][Full Text] [Related]
34. The interaction of von Willebrand factor-A1 domain with collagen: mutation G1324S (type 2M von Willebrand disease) impairs the conformational change in A1 domain induced by collagen.
Morales LD; Martin C; Cruz MA
J Thromb Haemost; 2006 Feb; 4(2):417-25. PubMed ID: 16420575
[TBL] [Abstract][Full Text] [Related]
35. Structure-function relationship of the A1 domain of von Willebrand factor.
Girma JP; Ribba AS; Meyer D
Thromb Haemost; 1995 Jul; 74(1):156-60. PubMed ID: 8578449
[TBL] [Abstract][Full Text] [Related]
36. Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease.
Ribba AS; Voorberg J; Meyer D; Pannekoek H; Pietu G
J Biol Chem; 1992 Nov; 267(32):23209-15. PubMed ID: 1429668
[TBL] [Abstract][Full Text] [Related]
37. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
[TBL] [Abstract][Full Text] [Related]
38. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K
Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727
[TBL] [Abstract][Full Text] [Related]
39. Structure and function of snake venom toxins interacting with human von Willebrand factor.
Matsui T; Hamako J
Toxicon; 2005 Jun; 45(8):1075-87. PubMed ID: 15922776
[TBL] [Abstract][Full Text] [Related]
40. Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex.
Andrews RK; Booth WJ; Gorman JJ; Castaldi PA; Berndt MC
Biochemistry; 1989 Oct; 28(21):8317-26. PubMed ID: 2557900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
